The U.S. Food and Drug Administration, in partnership with the Reagan-Udall Foundation for the FDA, holds a hybrid public meeting at 1 p.m. ET on Oct. 28 to gather input on its Rare Disease Framework Initiative. The meeting focuses on improving regulatory approaches to rare disease drug development, including evidence requirements, regulatory consistency, patient engagement, and manufacturing considerations for therapies targeting small patient populations. -- 🍀 Support NTD 👉 https://donate.ntd.com/ -- 📺 Watch NTD News 24/7 on cable, broadcast, and streaming: https://www.ntd.com/watch 🧶Exclusive Documentaries & Movies on NTD+: https://www.ntdplus.com/utm_source=YouTube&utm_medium=SocialM -- 🔵Sign up for our newsletter to stay informed with NTD News. 👉https://www.ntd.com/newsletter.htm?utm_source=YouTube. If the link is blocked, type in NTD.com manually to sign up. -- © All Rights Reserved.